This “Liposarcoma - Pipeline Insight, 2021” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Liposarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Liposarcomas are rare type of malignant tumors of fatty tissue. They are the second most common type of soft-tissue sarcoma. Liposarcoma can occur in fat cells in any part of the body, but most cases occur in the muscles of the limbs or in the abdomen. Liposarcomas are typically found in adults, typically between the ages of 40 and 60, and are rare in children. Liposarcoma occurs more often in men than women. Liposarcoma risk factors may include radiation, family cancer syndromes, a damaged lymph system, and/or exposure to certain chemicals. Liposarcoma stages describe the extent of tumor spread with stage IV representing the most extensive cancer with metastatic spread. Liposarcoma can be diagnosed by imaging the body by X-ray, computed tomography (CT) or magnetic resonance imaging (MRI). Therapy to treat liposarcoma largely depends on the type, size and location of the tumor. Treatments for liposarcoma include: Surgery, Radiation therapy, and Chemotherapy. New therapies are under clinical trials assessment as a potential treatment for liposarcomas.
"Liposarcoma - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Liposarcoma pipeline landscape is provided which includes the disease overview and Liposarcoma treatment guidelines. The assessment part of the report embraces, in depth Liposarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Liposarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Liposarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Liposarcoma.
This segment of the Liposarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
RAIN-32 (milademetan) is a small molecule based oral inhibitor of mouse double minute 2 (MDM2). MDM2 is a critical regulator of tumor protein 53 (p53), which is known as the “guardian of the genome”. RAIN-32 is in Phase III clinical studies for the treatment of Liposarcoma.
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. The molecule functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. Selinexor, with the brand name XPOVIO, has been approved by the USFDA for relapsed or refractory multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The drug is in Phase III clinical studies for the treatment of Liposarcoma.
This segment of the report provides insights about the different Liposarcoma drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 15+ key companies which are developing the therapies for Liposarcoma. The companies which have their Liposarcoma drug candidates in the most advanced stage, i.e. Phase III include, Rain Therapeutics.
This report covers around 15+ products under different phases of clinical development like
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Liposarcoma therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Liposarcoma drugs.
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Liposarcoma Understanding
Liposarcoma: Overview
Liposarcomas are rare type of malignant tumors of fatty tissue. They are the second most common type of soft-tissue sarcoma. Liposarcoma can occur in fat cells in any part of the body, but most cases occur in the muscles of the limbs or in the abdomen. Liposarcomas are typically found in adults, typically between the ages of 40 and 60, and are rare in children. Liposarcoma occurs more often in men than women. Liposarcoma risk factors may include radiation, family cancer syndromes, a damaged lymph system, and/or exposure to certain chemicals. Liposarcoma stages describe the extent of tumor spread with stage IV representing the most extensive cancer with metastatic spread. Liposarcoma can be diagnosed by imaging the body by X-ray, computed tomography (CT) or magnetic resonance imaging (MRI). Therapy to treat liposarcoma largely depends on the type, size and location of the tumor. Treatments for liposarcoma include: Surgery, Radiation therapy, and Chemotherapy. New therapies are under clinical trials assessment as a potential treatment for liposarcomas.
"Liposarcoma - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Liposarcoma pipeline landscape is provided which includes the disease overview and Liposarcoma treatment guidelines. The assessment part of the report embraces, in depth Liposarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Liposarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Liposarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Liposarcoma.
Liposarcoma Emerging Drugs Chapters
This segment of the Liposarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Liposarcoma Emerging Drugs
RAIN-32: Rain Therapeutics
RAIN-32 (milademetan) is a small molecule based oral inhibitor of mouse double minute 2 (MDM2). MDM2 is a critical regulator of tumor protein 53 (p53), which is known as the “guardian of the genome”. RAIN-32 is in Phase III clinical studies for the treatment of Liposarcoma.
Selinexor: Karyopharm Therapeutics
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. The molecule functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. Selinexor, with the brand name XPOVIO, has been approved by the USFDA for relapsed or refractory multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The drug is in Phase III clinical studies for the treatment of Liposarcoma.
Liposarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Liposarcoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Liposarcoma
There are approx. 15+ key companies which are developing the therapies for Liposarcoma. The companies which have their Liposarcoma drug candidates in the most advanced stage, i.e. Phase III include, Rain Therapeutics.
Phases
This report covers around 15+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Liposarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Liposarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Liposarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Liposarcoma drugs.
Liposarcoma Report Insights
- Liposarcoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Liposarcoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Liposarcoma drugs?
- How many Liposarcoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Liposarcoma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Liposarcoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Liposarcoma and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Karyopharm Therapeutics
- Rain Therapeutics
- Pfizer
- Sanofi
- Incyte Corporation
- Macrogenics
- Adaptimmune
- Merck KGaA
- GlaxoSmithKline
- Novartis Oncology
- Immune Design
- Syndivia
- TerSera Therapeutics
Key Products
- RAIN-32
- PF-07220060
- Selinexor
- Cabazitaxel
- Retifanlimab
- Afamitresgene autoleucel
- Avelumab
- Letetresgene autoleucel
- Ribociclib
- LV 305
- CMB 305
- SDV-1101
- Telotristat etiprate
Table of Contents
IntroductionExecutive Summary
Liposarcoma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Liposarcoma - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
RAIN-32: Rain Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Cabazitaxel: Sanofi
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
Ribociclib: Novartis Oncology
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
SDV-1101: Syndivia
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Liposarcoma Key Companies
Liposarcoma Key Products
Liposarcoma- Unmet Needs
Liposarcoma- Market Drivers and Barriers
Liposarcoma- Future Perspectives and Conclusion
Liposarcoma Analyst Views
AppendixList of Tables
Table 1 Total Products for Liposarcoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Liposarcoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Karyopharm Therapeutics
- Rain Therapeutics
- Pfizer
- Sanofi
- Incyte Corporation
- Macrogenics
- Adaptimmune
- Merck KGaA
- GlaxoSmithKline
- Novartis Oncology
- Immune Design
- Syndivia
- TerSera Therapeutics
